Ergomed plc

London-based Ergomed plc (AIM: ERGO LN; Xetra: 2EM GR) provides specialist services to the pharmaceutical industry spanning all phases of clinical trials, postapproval pharmacovigilance and medical information.

As a global CRO, Ergomed has a worldwide network designed to specifically match the requirements of today’s complex development and post marketing programs, enabling its clients to access solutions even for their toughest clinical development, pharmacovigilance (PV) and trial management challenges from early phase to complex late stage programmes. The company has provided and managed clinical development, trial management and pharmacovigilance services for over 100 clients, ranging from top 10 pharmaceutical and generics organizations to small and mid-sized drug development companies.

Ergomed at a glance:


Field of Activity
Pharmacovigilance & Clinical Research Organisation (CRO) Services across more than 100 countries to a range of international pharma, generic and biotech clients.
Ownership Structure and Financing Listing in London on the AIM market since July 2014; also traded in Frankfurt and on Xetra. Ergomed is cash-generative with a liquidity of £5.2 m at the end of 2018 with no debt.
Products/Services Ergomed‘s fast-growing, profi table services business includes a full range of high-quality contract research and trial management (CRO) services under the Ergomed brand together with an industry-leading suite of specialist pharmaco-vigilance solutions, integrated under the PrimeVigilance brand, and an inter-nationally recognised specialist expertise in orphan drug development, under the PSR brand.
Unique Selling Point As the only listed CRO in Europe, Ergomed offers a unique combination of full service CRO and PV with huge cross-selling potential between the two areas. Its wide geographic coverage and broad sector expertise in combination with inherently unique features such as the innovative Study Site Management model, the use of Study Physician Teams and its pioneering role in intelligent automation in its PV offering set Ergomed apart and see the company ideally positioned in a high growth industry that benefits from the increased outsourcing of drug development. This strong positioning has led to Ergomed growing at a CAGR of 18% p.a. since IPO.
Date of Incorporation/
Number of Employees



Dr. Miroslav Reljanović, Executive Chairman
1 Occam Court
The Surrey Research Park
Guildford, Surrey GU2 7HJ, United Kingdom
Telephone/Telefax +44 1483 503 205 / +44 1483 307 929
Web Address
Social media LinkedIn Twitter
Others Active in >100 countries with 16 offices worldwide